| Species Reactivity | Human |
| Clone | imneskibart |
| Source/Isotype | Human IgG1 (L234A, L235A), Kappa |
| Application | / |
| Target | Detects IL2 |
| Gene | IL2 |
| Other Names | IL-2; TCGF; lymphokine |
| Gene ID | 3558 (Human) |
| Background | IL2 is a master regulator of immune homeostasis, paradoxically driving both the expansion of effector T cells and the maintenance of immunosuppressive regulatory T cells (Tregs). Anti-IL2 monoclonal antibodies offer a precision tool to bias this signaling axis. In autoimmune diseases, Anti-IL2 strategies (particularly JES6-1-like clones or non-Fc-receptor-binding mutants) are being explored to selectively block IL2's engagement with high-affinity receptors on endothelium and NK cells, thereby shunting bioavailability toward Treg expansion for therapeutic tolerance. Conversely, in oncology, Anti-IL2 antibodies can be used to neutralize Treg-biased endogenous IL2 or, when complexed with IL2, form immunocytokines that preferentially stimulate cytotoxic CD8+ T cells over Tregs, enhancing anti-tumor immunity while mitigating vascular leak syndrome. Thus, Anti-IL2 research is pivotal for developing next-generation immunotherapies with tunable specificity. |
| Storage | Store at 2-8℃ short term (1-2 weeks). Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | imneskibart |
| Source/Isotype | Human IgG1 (L234A, L235A), Kappa |
| Application | / |
| Target | Detects IL2 |
| Gene | IL2 |
| Other Names | IL-2; TCGF; lymphokine |
| Gene ID | 3558 (Human) |
| Background | IL2 is a master regulator of immune homeostasis, paradoxically driving both the expansion of effector T cells and the maintenance of immunosuppressive regulatory T cells (Tregs). Anti-IL2 monoclonal antibodies offer a precision tool to bias this signaling axis. In autoimmune diseases, Anti-IL2 strategies (particularly JES6-1-like clones or non-Fc-receptor-binding mutants) are being explored to selectively block IL2's engagement with high-affinity receptors on endothelium and NK cells, thereby shunting bioavailability toward Treg expansion for therapeutic tolerance. Conversely, in oncology, Anti-IL2 antibodies can be used to neutralize Treg-biased endogenous IL2 or, when complexed with IL2, form immunocytokines that preferentially stimulate cytotoxic CD8+ T cells over Tregs, enhancing anti-tumor immunity while mitigating vascular leak syndrome. Thus, Anti-IL2 research is pivotal for developing next-generation immunotherapies with tunable specificity. |
| Storage | Store at 2-8℃ short term (1-2 weeks). Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
